1
Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo: Antibodies to insulin-like growth factor I receptor. Abgenix, Pfizer, Fish & Neave IP Group Ropes & Gray, James F Haley Jr Esq, Jane T Gunnison Esq, May 2, 2006: US07037498 (40 worldwide citation)

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single ...


2
William J Boyle, Francis H Martin, Jose R Corvalan, C Geoffrey Davis: Antibodies to OPGL. Amgen, Amgen Fremont, Finnegan Henderson Farabow Garrett & Dunner, April 29, 2008: US07364736 (16 worldwide citation)

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.


3
William J Boyle, Francis H Martin, Jose R Corvalan, C Geoffrey Davis: Polynucleotides encoding heavy and light chains of antibodies to OPGL. Amgen, Amgen Fremont, Finnegan Henderson Farabow Garrett and Dunner, November 15, 2011: US08058418 (11 worldwide citation)

Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.


4
Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo: Antibodies to insulin-like growth factor I receptor. Amgen Fremont, Pfizer, Ropes & Gray, Jane T Gunnison, Z Ying Li, April 20, 2010: US07700742 (5 worldwide citation)

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single ...


5
Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo: Antibodies to insulin-like growth factor I receptor. Amgen Fremont, Pfizer, Ropes & Gray, Jane T Gunnison, Z Ying Li, October 19, 2010: US07815907 (3 worldwide citation)

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single ...


6
Douglas C Hanson, Mark J Neveu, Eileen E Mueller, Jeffrey H Hanke, Steven C Gilman, C Geoffrey Davis, Jose R Corvalan: Nucleic acids encoding human monoclonal antibodies to CTLA-4. Amgen Fremont, Pfizer, Ropes & Gray, Jane T Gunnison, Z Ying Li, August 12, 2008: US07411057 (2 worldwide citation)

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and ...


7
William J Boyle, Francis H Martin, Jose R Corvalan, C Geoffrey Davis: Methods for treating bone loss with antibodies to OPGL. Amgen, Amgen Fremont, Finnegan Henderson Farabow Garrett & Dunner L, April 2, 2013: US08409578 (2 worldwide citation)

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.


8
Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo: Antibodies to insulin-like growth factor I receptor. Fish & Neave, May 6, 2004: US20040086503-A1

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single ...


9
Abraham Pinter, Yuxian He, Jose R Corvalan: Use of transgenic mice for the efficient isolation of novel human monoclonal antibodies with neutralizing activity against primary HIV-1 strains and novel HIV-1 neutralizing antibodies. Fish & Neave Ip Group, March 17, 2005: US20050058983-A1

The present invention relates to a novel human antibody, and antigen-binding portion thereof, that specifically binds HIV-1 gp120 protein and that has HIV-1 neutralizing activity. The present invention also relates to a cell line that produces an antibody of this invention. The present invention fur ...


10
C Geoffrey Davis, Russell W Blacher, Jose R Corvalan, Alan R Culwell, Larry L Green, Joanna Hales, Nancy Havrilla, Vladimir E Ivanov, John A Lipani, Qiang Liu, Richard F Weber, Xiao Dong Yang: CD147 binding molecules as therapeutics. Abgenix, Fish & Neave Ip Group, Ropes & Gray, March 1, 2007: US20070048305-A1

In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that ...